Progesterone Levels and Endometrial Compaction in Frozen-Thawed Embryo Transfer Cycles

January 8, 2021 updated by: Cem Demirel

The Correlation of Serum Progesterone Levels With the Degree of Endometrial Compaction on the Day of Frozen Embryo Transfer

This study is intended to determine whether there is a correlation between endometrial compaction and serum progesterone levels on the day of frozen embryo transfers by using transvaginal sonography for the endometrial assessment.

Study Overview

Detailed Description

This study is planned to be conducted by prospectively evaluating approximately 200 frozen embryo transfers within 6 months in a single center. Patients planned to be included in the study are started estrodiol 6 mg / day on day2-3 of mensturation. 12 days after the start of estrogen, patients who have endometrial thickness over 7 mm are then started vaginal progesterone supplementation as per routine practice and are eventually proceeded to embryo transfer either on day 4 or 6 of progesterone supplementation. In this study investigators are intended to measure endometrial thickness transvaginally on the day of embryo transfer to accurately determine the presence of endometrial compaction, assess serum progesterone levels, evaluate any possible correlations between endometrial compaction, serum progesterone levels and pregnancy rates.

Study Type

Observational

Enrollment (Anticipated)

200

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • İstanbul, Turkey, 34758
        • Recruiting
        • Ataşehir Memorial Hospital IVF Department
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

20 years to 40 years (ADULT)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

Female

Sampling Method

Non-Probability Sample

Study Population

Women underwent frozen embryo transfer

Description

Inclusion Criteria:

  1. Woman aged 20-40 years
  2. Hormonal(estrogen and progesterone) frozen- thawed embryo transfer cycles
  3. Having available blastocyst(s) cryopreserved by vitrification method.

Exclusion Criteria:

  1. Recurrent implantation failure
  2. Recurrent pregnancy loss
  3. Presence of uterine pathology
  4. Requirement for fresh embryo(s);
  5. Presence of any clinically relevant systemic disease contraindicated for assisted reproduction or pregnancy
  6. Allergy history for relevant drugs
  7. Body mass index of <18 or >38 kg/m2 at screening
  8. Current breastfeeding or pregnancy
  9. Refusal or inability to comply with the requirements of the protocol for any reason, including scheduled clinic visits and laboratory tests
  10. Natural or modified natural cycles

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
frozen embryo transfer cycles
patients undergoing frozen embryo transfer with artificial hormone replacement
transvaginal ultrasound performed on day of the start of progesterone supplementation and on the day of frozen embryo transfer; serum progesterone level measurement on day of frozen embryo transfer
Other Names:
  • serum progesterone level measurement

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Ongoing pregnancy rates
Time Frame: 12 weeks after the last menstrual period of the patient
Presence of at least one live fetus at the end of the 12th gestational week in patients with endometrial compaction compared to patients without endometrial compaction after frozen embryo transfer
12 weeks after the last menstrual period of the patient

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Implantation rate
Time Frame: 5 weeks after the last menstrual period of the patient
Percentage of gestational sacs compared to the number of embryos transferred
5 weeks after the last menstrual period of the patient
Clinical pregnancy rate
Time Frame: 6-7 weeks after the last menstrual period of the patient
Presence of an intrauterine gestational sac with fetal heart beat at 7th week of gestation
6-7 weeks after the last menstrual period of the patient
The Correlation of Serum Progesterone Levels With the Degree of Endometrial Compaction on the Day of Frozen Embryo Transfer
Time Frame: On the day of frozen embryo transfer
endometrium compacted (became thinner) after the administration of progesterone
On the day of frozen embryo transfer
Clinical miscarriage rate
Time Frame: after 5th gestational week
pregnancy loss after ultrasonographic detection of an intrauterine gestational sac
after 5th gestational week

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

June 15, 2020

Primary Completion (ANTICIPATED)

January 15, 2021

Study Completion (ANTICIPATED)

February 15, 2021

Study Registration Dates

First Submitted

September 4, 2020

First Submitted That Met QC Criteria

September 13, 2020

First Posted (ACTUAL)

September 18, 2020

Study Record Updates

Last Update Posted (ACTUAL)

January 11, 2021

Last Update Submitted That Met QC Criteria

January 8, 2021

Last Verified

January 1, 2021

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Infertility, Female

Clinical Trials on transvaginal ultrasound,

3
Subscribe